{"groups":[{"description":"Patients received 625 mg dordaviprone (ONC201) once weekly.\n\nArm A included patients with recurrent H3 K27M-mutant glioma including those with diffuse intrinsic pontine glioma (DIPG), primary spinal tumors, and some atypical histologies.","id":"FG000","title":"Arm A"},{"description":"Patients received 625 mg dordaviprone (ONC201) once weekly.\n\nArm B included patients with recurrent H3 K27M-mutant glioma, but excluded patients with the following:\n\n* Primary malignant lesion located in the pons or spinal cord.\n* Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).\n* Prior bevacizumab treatment of \\>4 doses of \\>7.5 mg/kg","id":"FG001","title":"Arm B"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"30"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}